



## **Global Submission Call for ‘Precision Oncology Patient Innovation’ Awards 2021**

As part of a continued commitment to the **worldwide** cancer community, Bayer is proud to support the first ‘Precision Oncology Patient Innovation Awards’. The 2021 Awards aim to foster innovation and collaboration to improve access to precision oncology care and tackle inequalities for people with cancer around the world. The Awards are particularly focused on helping people with cancer types that are known to harbor rare genomic alterations and which may benefit from tumor testing.

Programs may be relevant to pediatric or adult cancer communities.

Two grants are being offered in 2021 – one for \$50,000 and a second for \$25,000. Successful applications will be chosen by an independent Review Panel, comprised of leading experts from the clinical and patient advocacy cancer community.

Applicants can apply to support a new initiative or to support continued rollout/expansion of an existing program. Applying for the grant does not preclude organizations from seeking other sources of funding. Bayer will make every effort to help successful applicants share their programs with the wider cancer community.

**Who can apply?** The Awards are open to non-profit organizations from around the world\*, including patient advocacy groups, educational institutions and officially recognized healthcare/research facilities. [*\*Unless prohibited by national laws. Please check Program Criteria*]

**Deadline for applications:** Submissions must be received no later than midnight, EDT, on June 25, 2021

**Duration of Award:** 1 year

**Contact:** For queries about the Awards, please email the Program Secretariat at [PrecisionOncologyAwards@VozAdvisors.com](mailto:PrecisionOncologyAwards@VozAdvisors.com)

**For Application Forms and Program Criteria:**

<https://www.precisiononcologyawards.com/>

Precision oncology is a growing field where cancers are tested and treated according to their unique DNA fingerprint. Understanding what might be driving a person’s cancer growth, and their likely response to specific treatments, is intended to refine diagnosis and guide ongoing care.